BioNTech, DualityBio say ADC had ‘modest’ benefit in breast cancer study

The companies said the findings suggest the treatment has a limited impact in HER2-low breast cancer, an area where AstraZeneca and Daiichi Sankyo s Enhertu has already set a high bar.